Đang chuẩn bị liên kết để tải về tài liệu:
Apatinib treatment for KIT- and KDR-amplified angiosarcoma: A case report

Đang chuẩn bị nút TẢI XUỐNG, xin hãy chờ

Metastatic or relapsed angiosarcoma has a poor prognosis and the efficacy of conventional chemotherapy is often limited. Apatinib, a novel tyrosine kinase inhibitor (TKI) targeting vascular endothelial growth factor receptor-2 (VEGFR2), has been approved for the treatment of advanced gastric cancer. | Apatinib treatment for KIT- and KDR-amplified angiosarcoma A case report

TÀI LIỆU LIÊN QUAN

Effective treatment of apatinib in desmoplastic small round cell tumor: A case report and literature review

Apatinib treatment for KIT- and KDR-amplified angiosarcoma: A case report

Application effect of apatinib in patients with failure of standard treatment for advanced malignant tumours

Comparison of the efficacy and safety of transarterial chemoembolization with and without Apatinib for the treatment of BCLC stage C hepatocellular carcinoma

The efficacy and safety of apatinib treatment for patients with advanced or recurrent biliary tract cancer: A retrospective study

Efficacy and safety of apatinib in the treatment of osteosarcoma: A single-arm meta-analysis among Chinese patients

Treatment of consistent BRAF/HRAS gene mutation and MYC amplification radiationinduced abdominal wall angiosarcoma with low-dose apatinib: A case report
crossorigin="anonymous">
Đã phát hiện trình chặn quảng cáo AdBlock
Trang web này phụ thuộc vào doanh thu từ số lần hiển thị quảng cáo để tồn tại. Vui lòng tắt trình chặn quảng cáo của bạn hoặc tạm dừng tính năng chặn quảng cáo cho trang web này.